Vice President, Global Financial Control — Pharma Bridge

The mandate

The global controllership VP role carries consolidation adjustments, framework differences and transaction-related balances that require a consistent senior owner. The bridge must restore VP-level control accountability and challenge evidence without expanding the role into group CFO capital or commercial powers.

The term begins on 19 October 2026 for twelve months, based in Hyderabad with planned India entity visits and remote international controller reviews. A permanent controllership search runs alongside the appointment. The successor will join the final reporting cycles, and any extension must identify a remaining control-transfer condition rather than simply defer ownership of difficult accounting questions.

Handover requires a controlled entity-to-group reporting bridge, approved material judgement papers and a documented close calendar with independent review. Three global reporting cycles must demonstrate repeatable adjustment logic and clear exception ownership. The incoming VP must lead an entity challenge review and receive unresolved acquisition, impairment and framework issues with their evidence and approval histories.

Within the CFO's delegation, the VP may approve reporting procedures, accounting support schedules and routine application of existing policy. New accounting policy positions, material transaction commitments, permanent restructuring and statutory signatures remain with authorised officers or the board. Adjustments above the CFO-approved materiality threshold require independent review; the interim cannot define its own threshold simply to accelerate the close.

The bridge excludes clinical or manufacturing quality, capital-raising execution and a complete finance-system replacement. Its scope is reliable financial control in a pharmaceutical setting where inventory, intangible assets and cross-border reporting need thoughtful judgement. It must keep legal entity accountability visible, distinguish accounting evidence from transaction advocacy and leave retained controllers capable of sustaining the review after the temporary leader exits.

What you will own

• Approve entity-to-group reporting procedures that preserve local framework differences, adjustment rationale and independent review before consolidation amounts enter the global pack.
• Resolve judgement ownership for material pharma balances, distinguishing accounting-policy interpretation, evidence preparation and final approval within the CFO's existing delegation.
• Set a global exception register linking consolidation, impairment and transaction-related questions to source evidence, responsible controllers and dates for authorised resolution.
• Challenge inventory and intangible-asset assumptions through finance and operating evidence, referring specialist quality or valuation conclusions to their appointed owners rather than inferring them.
• Authorize close-review priorities by materiality and judgement risk, preventing routine reconciliations from crowding out balances whose basis remains contested or unsupported.
• Transfer the global control cycle through a successor-led entity review, including reproducible adjustments, unresolved policy matters and explicit statutory-signature boundaries.

Candidate qualifications

• Demonstrate genuine VP or equivalent global-controllership leadership in pharmaceuticals or comparable multi-entity operations, supported by a verifiable career chronology. Describe your personal authority over group reporting and a material judgement you defended, identifying the evidence accepted and the decisions retained by the CFO or statutory officers.
• Show strong practical command of Ind AS, IFRS and US GAAP interfaces relevant to your prior reporting remit. Provide an example where entity and group conclusions required a documented bridge rather than a balancing adjustment, and explain how local statutory accountability and group consistency were both preserved.
• Bring experience with pharmaceutical or similarly regulated manufacturing balances, including inventory, intangible assets, impairment and transaction-related accounting. Evidence should show a contested assumption, the operating or specialist information you obtained and the final reviewed treatment. Candidates are not presumed to supply clinical, quality or independent valuation opinions.
• Prove leadership of entity controllers across locations and successful transfer of a global reporting process. Explain how you handled conflicting close priorities, maintained reviewer independence and enabled another leader to reproduce the adjustment logic. Career duration and actual controllership scope must be substantiated; capital-market exposure alone does not establish readiness for executive control ownership.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 10 October 2026. Mandate reference PCT-INT-2026-IND-50.